×
For more information, get in touch with our team:
+44 7918 53 08 73
Hint mode is switched on Switch off
For swift navigation between sections

International bonds: Takeda Pharmaceutical, 0.375% 21nov2020, EUR
XS1843449981

DATA PLATFORM FOR FINANCIAL MARKET PROFESSIONALS AND INVESTORS
  • High performance interface for global bond market screening
  • Full information on close to 500,000 bonds from 180 countries
  • 100% coverage of Eurobonds worldwide
  • Over 300 primary sources of prices
  • Ratings data from all international and local ratings agencies
  • Stock market data from 100 world trading floors
  • Intuitive, high speed user interface
  • Data access via the website, mobile application and add-in for Microsoft Excel

Files

Trading chart

Stock exchange selection
Stock exchange selection
More about Cbonds Estimation
Bond is not traded; the issue is redeemed
Data display in a chart | table
Data display in a chart | table
Work with the chart: switching the price, period, issue comparison
Work with the chart: switching the price, period, issue comparison
Download the chart in a convenient format
Customize fields in the table
Found: {{ graphTablePointsTotal }}
Show all fields
* Data is not available within the selected subscription
Latest data on

Issue information

Profile
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The company’s drugs are marketed in approximately 90 countries worldwide. The company has an international marketing network, including Japan and 13 overseas bases in ...
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The company’s drugs are marketed in approximately 90 countries worldwide. The company has an international marketing network, including Japan and 13 overseas bases in the U.S., Europe, and Asia. From these bases, the company markets its original products.The company operates its business in two categories, Pharmaceutical business and Other businesses. The Pharmaceutical business represents the ethical drug business and healthcare business. Other businesses include business activities involving the production and marketing of a range of products, including clinical diagnostics, photographic chemicals, and inorganic chemicals. In November 2009, Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.Takeda Pharmaceutical Company Limited was founded in 1781.
Volume
  • Placement amount
    1,250,000,000 EUR
  • Outstanding amount
    1,250,000,000 EUR
Nominal
  • Minimum Settlement Amount
    100,000 EUR
  • Outstanding face value
    *** EUR
  • Par amount, integral multiple
    *** EUR
  • Nominal
    1,000 EUR

Cash flow parameters

  • Reference rate
    ***
  • Coupon Rate
    ***
  • Day count fraction
    ***
  • Business Day Convention
    Following Business Day
  • Interest Accrual Date
    ***
  • Coupon frequency
    *** time(s) per year
  • Payment currency
    ***
  • Delay days
    *** days
  • Maturity date
    ***
  • Early redemption date
    ***

Cash flow

Calculations for international bonds are made according to the minimum trading lot

Early redemption terms

***

DATA PLATFORM FOR FINANCIAL MARKET PROFESSIONALS AND INVESTORS
  • High performance interface for global bond market screening
  • Full information on close to 500,000 bonds from 180 countries
  • 100% coverage of Eurobonds worldwide
  • Over 300 primary sources of prices
  • Ratings data from all international and local ratings agencies
  • Stock market data from 100 world trading floors
  • Intuitive, high speed user interface
  • Data access via the website, mobile application and add-in for Microsoft Excel

Placement

  • Placement method
    Open subscription
  • Placement type
    Public
  • Order book
    *** (***) - *** (***)
  • Coupon (Yield) Guidance
    ***% - ***% (*** - ***%)
  • Issuer rating on issue date (M/S&P/F)
    *** / *** / -
  • Placement
    *** - ***
  • Initial issue price (yield)
    (***%)
  • Bids
    *** EUR
  • Number of bids
    ***
  • Geographic breakdown
    ***
  • Investor breakdown
    ***
  • Listing
    ***
Participants
  • Bookrunner
    ***, ***, ***, ***, ***, ***, ***, ***
  • Arranger Legal Adviser (International law)
    ***

Conversion and exchange

  • Convertion date
    ***
  • Initial premium
    ***%
  • Convertible until
    ***
  • Lock-up
    *** days
  • Conversion terms
    ***

Additional information

***

Latest issues

Identifiers

  • Registration
    ***
  • Date of program registration
    ***
  • ISIN RegS
    XS1843449981
  • ISIN 144A
    ***
  • CUSIP RegS
    ***
  • CUSIP 144A
    ***
  • Common Code RegS
    184344998
  • Common Code 144A
    184344955
  • CFI RegS
    DBVNBR
  • CFI 144A
    DBVNBR
  • FIGI RegS
    BBG00MKD90R1
  • FIGI 144A
    BBG00MKGMMM6
  • WKN RegS
    A2RUPJ
  • WKN 144A
    A2RUPK
  • Ticker
    TACHEM 0.375 11/21/20 REGS
  • Type of security by CBR
    ***

Ratings



Bond classification

  • Senior Unsecured
  • Registered
  • Coupon bonds
  • Amortization
  • Callable
  • CDO
  • Convertible
  • Dual currency bonds
  • Floating rate
  • For qualified investors (CIS region)
  • Foreign bonds
  • Green bonds
  • Indexed
  • Supranational bond issues
  • Mortgage bonds
  • Perpetual
  • Payment-in-kind
  • Non-Marketable Securities
  • Redemption Linked
  • Restructuring
  • Retail bonds
  • Covered
  • Securitization
  • Structured product
  • Subordinated
  • Sukuk
  • Trace-eligible

Restructuring

***

***